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Interest has increased in the potential role of circulating tumour cells in cancer management. Most cell-based studies have
been designed to determine the number of circulating tumour cells in a given volume of blood. Ability to understand the biol-
ogy of the cancer cells would increase the clinical potential. The purpose of this study was to develop and validate a novel,
widely applicable method for detection and characterisation of circulating tumour cells. Cells were imaged with an Image-
StreamX imaging flow cytometer which allows detection of expression of multiple biomarkers on each cell and produces high-
resolution images. Depletion of haematopoietic cells was by red cell lysis, leukocyte common antigen CD45 depletion and dif-
ferential centrifugation. Expression of epithelial cell adhesion molecule, cytokeratins, tumour-type-specific biomarkers and
CD45 was detected by immunofluorescence. Nuclei were identified with DAPI or DRAQ5 and brightfield images of cells were
collected. The method is notable for the dearth of cell damage, recoveries greater than 50%, speed and absence of reliance
on the expression of a single biomarker by the tumour cells. The high-quality images obtained ensure confidence in the speci-
ficity of the method. Validation of the methodology on samples from patients with oesophageal, hepatocellular, thyroid and
ovarian cancers confirms its utility and specificity. Importantly, this adaptable method is applicable to all tumour types includ-
ing those of nonepithelial origin. The ability to measure simultaneously the expression of multiple biomarkers will facilitate
analysis of the cancer cell biology of individual circulating tumour cells.
Detection of circulating tumour cells (CTCs) was first
reported more than a century ago.1 Interest in the clinical
role of CTCs has increased with the development of
improved technologies for their detection. The initial focus of
research on cell-based detection has been on the enumeration
of CTCs. Studies have sought evidence that the burden of
tumour cells in the circulation of patients with advanced can-
cer provides prognostic or predictive information. High num-
bers of CTCs in patients undergoing chemotherapy for
metastatic breast, colorectal and prostate cancer are associ-
ated with poor patient prognosis.2–4
The introduction of novel agents that target-specific
molecular aberrations within cancer cells has driven explora-
tion for biomarkers with which to inform accurate stratifica-
tion of patients. Currently, biomarker profiles of tumour cells
are measured on material obtained by surgical resection or
invasive biopsy. CTCs are a source of disseminated malignant
cells from which information about biological properties, or
pharmacodynamic responses to novel therapeutics, may be
obtained noninvasively.
Effective enumeration and characterisation depend upon a
reliable method for the evaluation of CTCs. Detection of
small populations of CTCs within the large number of nor-
mal blood cells represents a significant technical challenge. A
single CTC may be detected in 7.5 ml of blood,5 a volume
that may contain up to 75 million leukocytes and 50 billion
erythrocytes. Enrichment of the sample is required before
tumour cell identification and characterisation can occur.
This enrichment may consist of positive selection of the
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CTCs, positive depletion of the normal blood cells or a com-
bination of the two approaches. A perfect method would
remove completely the red blood cells, white blood cells and
platelets, produce no cellular debris and recover all the CTCs.
The majority of clinical studies reported have relied upon
positive selection of tumour cells that express a single bio-
marker.6–13 The antigen chosen most commonly is epithelial
cell adhesion molecule (EpCAM).
We sought to develop a method for identification, quanti-
fication and characterisation of CTCs that would not rely
upon expression of a single antigen and would be applicable
to multiple tumour types. Additional aims were to obtain
high-resolution images of the cells, avoid cell damage, achieve
high sensitivity and specificity and have the ability to analyse
the expression of multiple biomarkers in each tumour cell.
We report the development of our method, and its validation
with whole blood from patients with oesophageal, hepatocel-
lular, thyroid and ovarian cancers.
Materials and Methods
Tissue culture
SK-GT-4 oesophageal adenocarcinoma cells (DSMZ,
Braunschweig, Germany) and OVCAR-3 ovarian cancer cells
(ATCC) were grown in RPMI supplemented with 10% foetal
calf serum (FCS). ML1 thyroid cells (DSMZ, Braunschweig,
Germany) were grown in DMEM supplemented with 10% FCS
(Life Technologies, Paisley, UK). Huh-7 hepatocellular carci-
noma cells (ATCC) were grown in DMEM with F12 Ham’s
nutrient and 10% FCS. All other reagents were purchased from
Sigma-Aldrich (Poole, UK) unless stated otherwise.
Cells were maintained in exponential growth at 378C in a
humidified atmosphere, supplied with 5% CO2 and discarded
after the 30th passage. Cells were confirmed to be myco-
plasma free (MycoAlert mycoplasma detection kit; Lonza).
Immunofluorescence
Cells were fixed by incubation in 0.4% formaldehyde for 20
min, or Phosflow Lyse/Fix buffer (BD, Oxford, UK) and per-
meabilised by incubation in Perm/Wash buffer (BD, Oxford,
UK) for 1 hr at room temperature. Cells were incubated with
1:20 antipan-cytokeratin (clone C-11) PE (Cayman Chemical)
and appropriate tumour-specific intracellular antibodies for
30 min at room temperature: 1:50 antisurvivin Alexa FluorV
R
647 (Cell Signaling); 1:50 antiMUC16 which is known as
carcinoma antigen 125 (CA-125) (Abcam) Alexa FluorVR 594,
conjugated with an APEXTM kit (Invitrogen) as per manufac-
turer’s instructions; 1:50 antialpha faetoprotein Alexa FluorV
R
594 (Cell Signaling). Membrane antibodies and nuclear stains
were added and incubated for 1 hr at room temperature: 1:20
anti-CD45 (clone H130) V450 or PE:Cy7 (BD Biosciences);
1:20 anti-EpCAM CD326 (clone 9C4) Alexa FluorVR 488 (Biol-
egend); DAPI or DRAQ5 (Biostatus, UK). Cells from thyroid
cancer patients were incubated first with 1:50 antisodium:io-
dide symporter (NIS; Milipore) followed by anti-mouse Texas
Red (Life Technologies, UK). Subsequent incubations were as
described above except that the anti EpCAM CD326 (clone
9C4) was conjugated to PerCP:Cy5.5 (Biolegend). Cells were
washed in 500 ml of Perm/Wash buffer and recovered by cen-
trifugation at 500 g for 5 min and either analysed immediately
or stored as a pellet at 48C until analysis.
High-resolution flow cytometry
Cells were resuspended in phosphate-buffered saline (PBS)
and divided into 60 ml aliquots. Aliquots were analysed with
an ImageStreamX (Amnis) image flow cytometer with an 8-
mm core at 60 mm/sec with 7% Speed BeadsVR . Speed BeadsVR
are a 1 lm polystyrene beads that allow calibration of the
flow and focus of the ImageStreamX. Fluorochromes were
excited with 405, 488, 561 and 642 nm lasers and light emit-
ted by the fluorescently-labelled cells was collected through a
340 objective. Of the twelve channels available, channels 1
and 9 were reserved for brightfield images. The other chan-
nels were set to collect magnified emitted light with two
CCD cameras, each spatially resolved into five distinct spec-
tral bandwidths, over a range of wavelengths between 430
and 745 nm. Single-colour reference samples for each fluoro-
chrome were generated by inclusion of cells that had been
incubated with each antibody separately. A compensation
matrix was built with the data from single-colour reference
samples to allow removal of spectral overlap to adjacent chan-
nels from each detection channel. The diameters of individual
cells detected were measured and are given as means6 stan-
dard errors of the mean for different populations of cells.
Detection of cells in whole blood
Ethical approval for the study was obtained from the New-
castle and North Tyneside Research Ethics Committee. An
initial predraw of 4 ml of blood was discarded to reduce
What’s new?
Circulating tumour cells (CTCs) are disseminated malignant cells from which biological and therapeutic information may be
obtained non-invasively. Detection of small CTC populations within the large number of normal blood cells is a challenge. This
study describes a novel method for the detection and high-resolution imaging of CTCs. Unlike most other studies, CTC detec-
tion is not reliant upon expression of a single biomarker. The method is applicable to all cancers; the authors present prelimi-
nary results from four tumour types. The high quality of the images allows biological characterisation of the tumour cells and
increases the clinical potential of the approach.
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contamination with epithelial skin cells. Blood samples were
collected in Transfix collection tubes (Cytomark, UK) to store
for up to 24 hr at 48C or BD Vacutainer EDTA tubes (BD
Biosciences) for immediate use.
For each cell recovery experiment, 12 ml-blood samples
were collected from healthy volunteers. Cells from cancer cell
lines were trypsinised and resuspended in media. Cells were
counted with an improved Neubauer haemocytometer
(Hawksley, UK) and were diluted twice by 1 in 10. The
appropriate volume of cells containing 2,000, 200 or 20 cells
was added to 4 ml blood samples to give 500, 50 and 5
malignant cells/ml of whole blood.
To determine the contribution of the final stage of the
imaging flow cytometric analysis to the overall recovery rates,
500 unprocessed cells were analysed directly with the Image-
StreamX flow cytometer. Cells were imaged in the brightfield
channel and images with cellular morphology were counted.
Analysis of patient samples
Whole blood samples were obtained from patients under-
going treatment for oesophageal adenocarcinoma, hepatocel-
lular carcinoma, thyroid carcinoma or ovarian cancer at the
Newcastle-upon-Tyne and Gateshead NHS Foundation
Trusts, UK. Patient clinical data was recorded for each
patient in accordance with ethical approval. In addition
whole blood samples were obtained from healthy volunteers
who had no medical history of any current or previous can-
cer. CTCs were defined by the presence of at least one
tumour-specific antigen, the absence of CD45, the presence
of a nucleus and cellular morphology as assessed by bright-
field imaging. CTC images were verified independently by
two members of the research group.
Depletion of haematopoietic cells
Patient and healthy volunteer samples were processed to
enrich for nonhaematopoietic cells prior to analysis. Cells
were transferred into 50 ml Falcon tubes, incubated in 5 ml
of 5% bovine serum albumin (BSA) in AutoMACS rinse
solution (Miltentyi Biotec, Germany). Human FcR blocking
reagent (Miltenyi Biotec, Germany) was added directly to the
blood to a final dilution of 1:40 to prevent nonspecific anti-
body binding. Red blood cells were lysed, and all other cells
fixed, by incubation in BD Phosflow Lyse/Fix buffer 1:20
(v:v; BD Biosciences) for 15 min at 378C. Fixed, unlysed cells
were collected by centrifugation at 500 g at room tempera-
ture for 8 min. The supernatant was discarded and the cells
were resuspended in 500 ml RoboSep buffer (Stemcell Tech-
nologies, UK) in a polystyrene Falcon tube (BD Biosciences).
White blood cells were removed with an EasySep human
CD45 depletion kit (Stemcell Technologies, UK) as per the
manufacturer’s instructions. Briefly, antibodies against CD45,
bound in tetrameric complexes were added to the cell sus-
pension and incubated for 15 min at room temperature.
Dextran-coated magnetic nanoparticles were added and incu-
bated with the cells for 10 min at room temperature. The cell
suspension was diluted in 5 ml of Robosep buffer and placed
in an EasySepTM big easy magnet (Stemcell Technologies,
UK) for 10 min at room temperature. The unretained cell
Figure 1. EpCAM, cytokeratin, survivin and CD45 expression in oesophageal adenocarcinoma cells and in white blood cells. SK-GT-4 cells
were grown to 80% confluence in routine culture medium, trypsinised and 1 3 106 cells fixed with 1% formalin. Cells were permeabilised
by incubation with 0.3% saponin, incubated overnight with antibodies against cytokeratins 4, 5, 6, 8, 10, 13 and 18, and CD45, and incu-
bated subsequently with antibodies against EpCAM and survivin. Cells were washed, re-suspended in 100 ll and 2 ll DAPI added. Cells
were visualised with an ImageStreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 and 658 nm (a). Red blood
cells were removed from whole blood by ammonium chloride lysis, the remaining blood cells were concentrated by centrifugation, fixed,
permeabilised and incubated with antibodies against EpCAM, cytokeratins 4, 5, 6, 8, 10, 13 and 18, survivin and CD45 as in (a). Blood
cells were concentrated, incubated with DAPI and visualised (b). Images were collected with a 340 objective with the wavelengths for the
collection channels set at: 480–560 nm, EpCAM; 560–595 nm, cytokeratins; 745–800 nm, CD45; 430–505 nm, DAPI; and 642–745 nm,
survivin.
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fraction was decanted into a clean tube by inversion of the
sample and magnet. The recovered cells were centrifuged at
250 g for 5 min, resuspended in 1 ml Perm/Wash buffer
(BD, Oxford, UK), incubated for 1 hr at room temperature
and processed for analysis by image flow cytometry.
Results
Image flow cytometry of malignant cells
Four distinct tumour types were selected for development of
a universal method for detection of CTCs. Expression of
EpCAM and cytokeratins 4, 5, 6, 8, 10, 13 and 18 was chosen
for detection of the malignant cells. In addition, detection of
expression of tumour- or tissue-specific markers was
included: for hepatocellular carcinoma, alpha-faetoprotein;
for thyroid carcinoma, thyroglobulin and sodium:iodide sym-
porter (NIS) and for ovarian cancer, cancer antigen 125 (CA-
125). There is no accepted tumour-specific marker for oeso-
phageal adenocarcinoma, but survivin expression is reported
to be high and measurement of its expression was included
for this tumour type.
Initially, detection was optimised with established cell
lines. SK-GT-4 oesophageal adenocarcinoma cells were incu-
bated with fluorescently-conjugated antibodies against
EpCAM, cytokeratins 4, 5, 6, 8, 10, 13 and 18, and with
DAPI, a fluorescent dye that binds DNA. A fourth conju-
gated antibody against leukocyte common antigen CD45 was
included because it would allow subsequent discrimination of
leukocytes. Cells were analysed for expression of the antigens
with an ImageStreamX image flow cytometer. Representative
images from three cells are shown in Figure 1a. The different
images obtained from a single cell are shown in each hori-
zontal panel. The brightfield image of the cell shown on the
left hand side of each panel allows visualisation of the
nucleus, plasma membrane and overall cell morphology. All
three cells have cytoplasmic immunoreaction for EpCAM,
with some evidence of intracellular vesicular accumulation
and membrane localisation. The immunoreaction for the
cytokeratins was less intense, but evident in the cytoplasmic
compartment of all cells. Survivin expression was detected in
the nuclei of the cells coincident with the localisation of the
DAPI DNA dye. The composite images shown on the right
hand side of the panels confirm localisation of EpCAM and
the cytokeratins in the cytoplasmic and membrane compart-
ments of the cells and the distinct localisation of survivin in
the nuclei. Expression of CD45 was not detected in SK-GT-4
oesophageal adenocarcinoma cells.
Hepatocellular Huh-7 cells, ML1 thyroid cells and
OVCAR 3 ovarian cells were analysed as described above
except that the antibody against survivin was replaced with
antibodies against alpha-faetoprotein, thyroglobulin and NIS,
and CA-125, respectively. Images of comparable quality to
those shown in Figure 1a were obtained for all three cell lines
(data not shown). Alpha-faetoprotein, thyroglobulin and NIS,
and CA-125 were detected in Huh-7, ML1 and OVCAR 3
cells, respectively. These results demonstrate the applicability
of the method to the detection of multiple tumour types, the
measurement of tumour-type-specific biomarkers and the
high quality of the images that may be obtained.
Detection of malignant cells in, and recovery from,
whole blood
It was important to demonstrate the specificity of our
method with whole blood from healthy individuals. Blood
was collected, red blood cells were lysed and the remaining
blood cells collected by centrifugation. These blood cells were
incubated with antibodies against EpCAM, cytokeratins 4, 5,
6, 8, 10, 13 and 18, survivin and CD45, centrifuged at low g-
force to remove platelets and analysed for expression of the
antigens by image flow cytometry (Fig. 1b). The brightfield
images demonstrate that the cells detected are of smaller
diameter (12.26 0.2 mm) than the SK-GT-4 oesophageal cells
(20.36 0.2 mm; unpaired t test, p< 0.001); nearly all express
CD45. Fifty-three blood samples from healthy individuals
have been analysed with the tumour-specific antibodies. No
cells were detected with morphology consistent with a malig-
nant cell and expression of a tumour-specific antigen. These
results indicate that the detection method will discriminate
effectively nonhaematopoietic cells from haematopoietic cells.
Despite the ability of the ImageStreamX flow cytometer to
image 2,000 cells/sec, the large number of cells in whole blood
means that analysis is extremely lengthy and produces an
enormous amount of data for analysis and storage. We investi-
gated the best method with which to enrich blood for nonhae-
matopoietic cells. For these experiments, known numbers of
Figure 2. Enrichment for nonhaematopoietic cells. Cultured malig-
nant cells were added to 4 ml of whole blood and cells were incu-
bated with tetrameric antibody complexes against CD45 and
dextran-coated magnetic particles for 1 hr and placed in an Easy-
Sep Big Easy magnet. Cells not attracted to the magnet were recov-
ered. The number of leukocytes was counted with a
haemocytometer prior to and after depletion. Erythrocytes were
removed by lysis and platelets by centrifugation at 250 g.
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cultured malignant cells were added to samples of whole blood
and then the malignant cells were purified and analysed by
image flow cytometry. Positive selection of the malignant cells
involved identification of a universally expressed antigen or
differential separation on the basis of density. All methods
tested gave low recovery of the malignant cells and the cells
that were recovered were damaged physically as assessed by
the images produced (data not shown). We therefore devel-
oped a method for positive depletion of haematopoietic cells.
After initial lysis of the erythrocytes; the leukocytes, platelets
and malignant cells were incubated with tetrameric antibody
complexes against CD45 and dextran-coated magnetic par-
ticles. The cells were placed in a magnet and those not
attracted to the magnet were recovered. The method was opti-
mised to minimise loss of nonhaematopoietic cells whilst maxi-
mising depletion of CD45 positive cells.
Depletion of leukocytes was consistently 956 0.8% (Fig. 2).
The recovered cells were incubated with detection antibodies
and DAPI, centrifuged at 250 g to remove platelets and ana-
lysed by high-resolution image flow cytometry as described
above. Analysis of cells enriched from 1 ml of blood takes 20
min in the ImageStreamX flow cytometer whereas analysis of
1 ml of blood without prior enrichment takes 180 min. Images
of the malignant cells and residual leukocytes were similar to
those shown in Figure 1, which confirms that minimal damage
to the malignant cells is caused by this enrichment method of
positive blood cell depletion (data not shown).
The malignant cells are distinguished from residual leuko-
cytes by expression of epithelial cell- and tumour-specific
antigens, absence of expression of CD45, and by their mor-
phology and larger size. Analysis of the images obtained with
the IDEAS Software enables automatic discrimination of the
two cell populations. The first selection is based upon the
intensity of the nuclear dye retained by the cells (Fig. 3a).
The sharp peak around zero contains beads and small par-
ticles of debris. The peak of intensity between 3 and 4 3 105
fluorescence units contains single leukocytes. The third peak
of intensity between 5 and 8 3 105 fluorescence units con-
tains malignant cells and doublets of white blood cells and is
analysed further. Subsequent selection is based upon absence
of CD45 expression and presence of expression of EpCAM,
cytokeratins and survivin, alpha-faetoprotein, thyroglobulin,
NIS or CA-125. The effectiveness of the discrimination is
illustrated in Figure 3b; one population of cells expresses
CD45 but not EpCAM while the second population expresses
EpCAM but not CD45. Cells that express one or more of the
epithelial- or tumour-specific antigens and do not express
CD45 are selected automatically with the IDEAS Software.
The images of each of these cells are examined visually to
confirm that they have a cellular morphology as shown in
Figure 1 and that the IDEAS Software is able to distinguish
the malignant cells from any residual haematopoietic cells.
We processed, imaged and analysed 5 ml blood samples
from 24 healthy volunteers as described above. Blood was
enriched by CD45-positive cell depletion, incubated with the
detection antibodies and analysed by ImageStreamX flow
cytometry. The majority of the residual white blood cells
were detected with the CD45 antibody. None of the cells
imaged within the healthy volunteer samples met the criteria
for classification as a CTC.
Figure 3. Discrimination of the malignant cell population in whole blood from the residual leukocytes after positive depletion of blood cells.
Cultured malignant SK-GT-4 cells were added to 4 ml of whole blood. Erythrocytes were removed by ammonium chloride lysis and platelets
by centrifugation at 250 g. The cells in the supernatant were incubated with tetrameric antibody complexes against CD45 and dextran-
coated magnetic particles for 1 hr and placed in an EasySep Big Easy magnet. The cells not attracted to the magnet were recovered and
analysed in an ImageStreamX flow cytometer as described in the legend to Figure 1. The number of images at each DAPI fluorescence inten-
sity is shown (a). The intensity of fluorescence for the CD45 antibody is compared with the intensity of fluorescence of the EpCAM antibody
for all cells distinguished (b).
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The efficiency of recovery of malignant oesophageal, hepa-
tocellular, thyroid and ovarian cells from whole blood was
evaluated. The cell recovery across the four tumour types was
57.36 3.6, 49.26 3.9 and 59.06 5.6% from 500, 50 and 5
cells/ml of blood, respectively (Fig. 4). We investigated specif-
ically the recovery during the final analysis with the image
flow cytometer. The recovery during analysis of known num-
bers of cells by image flow cytometry was 89.21/26.2%,
which means that the recovery during the red blood cell lysis,
white blood cell depletion, centrifugation and antibody label-
ling steps was 61.9% to give an overall recovery of 55.2%.
Detection and analysis of circulating tumour cells
To validate the method, blood samples from six individual
patients with oesophageal, hepatocellular, thyroid and ovarian
cancer were analysed essentially as described above. Repre-
sentative images of tumour cells detected for each of the four
tumour types are shown in Figure 5. The morphology of the
oesophageal tumour cells detected was similar to that of the
cultured cells. All of the oesophageal CTCs detected
expressed EpCAM, cytokeratins and survivin. CTCs were
detected in two of the six oesophageal adenocarcinoma
patients analysed (Table 1). None of these patients had mac-
roscopic evidence of metastatic disease. The mean diameter
of all the circulating oesophageal adenocarcinoma cells
detected was 17.26 0.4 mm.
CTCs were detected in blood from four out of six patients
with hepatocellular carcinoma (Figs. 5b and 5c). Some of the
CTCs from patient seven expressed EpCAM but cytokeratins
were not detected, and other cells expressed cytokeratins but
EpCAM expression was not detected. None of the CTCs from
this patient expressed alpha-faetoprotein. Alpha-faetoprotein
was detected in cells from patient ten that did not express
EpCAM or the cytokeratins (Fig. 5c). The morphology of the
hepatocellular tumour cells varied. The diameter of the hepato-
cellular carcinoma cells was 216 0.6 mm which is significantly
larger than the diameter of the CTCs from all three other
tumour types (unpaired t test, p< 0.001)
CTCs were detected in three of the six patients with thy-
roid cancer. The majority of these tumour cells expressed
cytokeratins, thyroglobulin and NIS. EpCAM expression was
low or undetectable. The highest number of CTCs was
detected in blood from a patient with known metastatic dis-
ease. A third of their CTCs had clear membrane and cyto-
plasmic immunoreactivity for thryoglobulin, NIS and
cytokeratins, no obvious morphological damage and well-
defined oval nuclei (Fig. 5d). These CTCs stained intensely
with DAPI possibly because they were aneuploid or were in
the G2 stage of the cell cycle. The other cells expressed lower
levels of cytokeratins, did not express detectable levels of thy-
roglobulin, NIS or EpCAM and stained less intensely with
DAPI (Fig. 5d). These differences may represent heterogene-
ity of expression of biomarkers within the cells or the second
group of cells may be undergoing cell death. The diameter of
the circulating thyroid cancer cells was 166 0.3 mm.
CTCs were detected in blood from four out of six patients
with ovarian cancer. The cells all expressed EpCAM and
cytokeratins. CA-125 expression was detected in around half
of the tumour cells (Fig. 5e). The diameter of the CTCs
detected in blood from ovarian cancer patients was
13.66 0.59 mm. This diameter was significantly smaller than
the diameters of CTCs detected in oesophageal adenocarci-
noma, thyroid cancer and hepatocellular carcinoma patients
(p< 0.001).
Discussion
We report a method for the detection and accurate character-
isation of CTCs by high-resolution image flow cytometry.
We demonstrate that this method is reproducible in samples
from four tumour types. EpCAM was included within our
panel of antigens, but could be replaced with other bio-
markers for detection of nonepithelial malignant cells. Simi-
larly as novel biomarkers are discovered, analysis of these
could be incorporated. The method could be adapted also for
measurement of pharmacodynamic biomarkers. The process
of enrichment that we describe is based exclusively upon the
positive depletion of haematological cells. Following this
Figure 4. Retrieval of malignant cells from whole blood. SK-GT-4,
Huh-7, ML1 and OVCAR 3 cells were added to 4 ml of whole blood
to give a final concentration of 500, 50 and 5 malignant cells/ml.
The samples were enriched for malignant cells by depletion of
blood cells and the residual cells were incubated with fluorescent
antibodies and nuclear dye and analysed by high-resolution flow
cytometry as described in the Materials and Method. The mean
recoveries (6SEM) across the four tumour types were 57.363.6,
49.263.9 and 59.065.6% from 500, 50 and 5 cells/ml of blood,
respectively. Experiments were replicated at least thrice.
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Figure 5. Detection of circulating tumour cells in blood from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Blood
was obtained from patients, enriched for nonhaematopoietic cells and incubated with antibodies against EpCAM, cytokeratins 4, 5, 6, 8, 10,
13 and 18, CD45 and either survivin (oesophageal; a), alpha-faetoprotein (AFP) (hepatocellular; b and c), thyroglobulin and sodium:iodide
symporter (thyroid; d) or CA-125 (ovarian; e). Cells were incubated with DAPI (a and d) or DRAQ5 (b, c and e) and analysed by high-resolution
flow cytometry. Representative images of cells are shown. Small particles visible in some brightfield images represent the Speed Beads
VR
that
are added to allow calibration of the objective and camera.
depletion, CTCs are distinguished from residual leukocytes
and cellular debris by analysis of the expression of multiple
antigens and by examination of cellular morphology in the
high quality images.
The main focus of CTC research has been the value of
CTC enumeration for prognosis discrimination in patients
with metastatic disease and for prediction of response to
cytotoxic therapy. Levels of CTCs are associated with overall
Table 1. Patient demographics and numbers of circulating tumour cells in blood from patients with oesophageal, hepatocellular, thyroid and
ovarian cancers
Patient
no.
Tumour
origin Tumour type Sex Age
Disease
stage1
Distant
metastatic
disease
Previous
therapy
CTCs
detected2
CTCs
in
7.5 ml
1 Oesophagus Adenocarcinoma Male 59 T2N2M0 No No 43 64
2 Oesophagus Adenocarcinoma Male 63 T3N2M0 No No 17 27
3 Oesophagus Adenocarcinoma Male 83 T1N0M0 No No 0 0
4 Oesophagus Adenocarcinoma Female 74 T3N1M0 No No 0 0
5 Oesophagus Adenocarcinoma Male 65 T2N0M0 No No 0 0
6 Oesophagus Adenocarcinoma Male 72 T3N2M0 No No 0 0
7 Liver Hepatocellular
carcinoma
Male 70 T1N0M0 No TACE3/SIRT4 20 37
8 Liver Hepatocellular
carcinoma
Female 62 T2N0M0 No TACE3 0 0
9 Liver Hepatocellular
carcinoma
Male 93 Unknown No No 0 0
10 Liver Hepatocellular
carcinoma
Male 75 T3bN0M0 No No 9 16
11 Liver Hepatocellular
carcinoma
Male 81 T1N0M0 No TACE3 2 4
12 Liver Hepatocellular
carcinoma
Female 85 T1N0M0 No TACE3 2 4
13 Thyroid Medullary thyroid
cancer
Male 49 T2N2M1 Yes Surgery 4 4
14 Thyroid Multifocal follicular
variant of papillary
thyroid cancer
Female 29 T1aN0M0 No Surgery
Thyroxine
0 0
15 Thyroid Follicular thyroid
cancer
Female 47 T2N0M0 No Surgery
Thyroxine
Radioiodine
1 1
16 Thyroid Papillary thyroid
cancer
Male 61 T4N2M1 Yes Surgery
Thyroxine
Radioiodine
radiotherapy
118 118
17 Thyroid Follicular variant
of papillary
thyroid cancer
Female 52 T3N0M0 No Surgery
Thyroxine
Radioiodine
0 0
18 Thyroid Follicular variant of
papillary thyroid
cancer
Female 50 T2N0M0 No Surgery
Thyroxine
Radioiodine
1 1
19 Ovary Serous Female 50 FIGO Stage 4 Yes No 30 45
20 Ovary Serous Female 66 FIGO Stage 3c Yes No 15 23
21 Ovary Mucinous Female 75 FIGO Stage 3c Yes No 5 8
22 Ovary Serous Female 54 FIGO Stage 3c Yes No 0 0
23 Ovary Serous Female 85 FIGO Stage 4 Yes No 4 6
24 Ovary Serous Female 72 FIGO Stage 3c Yes No 0 0
1Disease stage is provided according to the latest UICC TNM classification for oesophageal, hepatocellular and thyroid cancer, and the FIGO classifi-
cation is shown for ovarian cancer.
2The volume of blood analysed was 5 ml for patients with oesophageal and ovarian cancers, 4 ml for those with hepatocellular carcinoma and
7.5 ml for thyroid cancer patients.
3Transarterial chemoembolisation.
4Selective internal radiotherapy treatment.
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survival in pre- and on-treatment patients with metastatic
breast cancer, metastatic colorectal cancer and castration-
resistant prostate cancer.2,3,14–19 The numbers of CTCs
detected in patients with metastatic cancer are often low, and
because detection of a single CTC may determine whether a
patient is categorised into a good or a bad prognostic
group,2,3 it is important that all CTCs are detected, not only
specific subpopulations. A strength of our method is that it
permits detection of heterogeneity within a patient’s CTC
population (Fig. 5d).
There is considerable interest in the analysis of CTCs as a
means of studying the biology and behaviour of metastatic
cancer. Metastatic disease is frequently difficult to biopsy
and treatment is based usually on analysis of the primary
tumour. Specific protein expression in metastatic disease may
differ from that of the primary tumour.20,21 The capability to
detect multiple antigens simultaneously enables detailed
molecular characterisation of CTCs and may provide an
accurate assessment of the biology of the underlying meta-
static disease.
It is important that the specificity of CTC detection is
high. There is no consensus definition as to what constitutes
a CTC partly because of the large number of techniques used
for their detection. Variation in the phenotypic criteria by
which CTCs are defined results in different CTC counts with
varying degrees of clinical significance.22 The majority of
studies define CTCs based upon positive and negative antigen
expression. In some studies, molecular definition is combined
with cell morphology. The high-resolution imaging that we
describe allows us to discriminate objects that might other-
wise have been included in the enumeration of CTCs. Some
studies11,23–32 have reported substantially larger numbers of
CTCs than have been identified in the present study or in
other reports.2,3 It is possible that such high numbers reflect
inclusion of noncellular objects and cellular debris.
Analysis of CTCs without enrichment is achievable with
an ImageStreamX flow cytometer, but the time required to
process an unenriched sample precludes realistic routine clin-
ical application. Analysis of one unenriched 5 ml blood sam-
ple would take 15 hr compared to 1 hr 40 min for an
enriched sample. The losses in our method occur predomi-
nantly during the enrichment and antigen detection stages.
The recovery of cells during the final analysis with the
ImageStreamX flow cytometer is 89.2%. The overall loss from
the procedure is 44.8%, of which 38.1% is lost during the
enrichment and 6.7% during the image collection. The Easy-
Sep CD45 depletion kit achieved the optimal recovery of
CTCs without generating large quantities of cellular debris.
Recovery rates are comparable with other methods in which
leukocytes are depleted positively33,34 and were consistent
over a range of cell concentrations for all tumour types. Leu-
kocyte depletion in head and neck cancers has been evaluated
by fluorescent activated cell sorting with a variety of com-
mercially available anti-CD45 antibodies and magnetic par-
ticles including EasySep.34 Recovery rates of up to 86% were
reported but in these analyses, cells were added to buffy coat
rather than whole blood, which should give higher recovery
rates because the losses associated with red cell lysis are not
considered.35
The most widely used method for cell-based CTC analysis
is the CellSearch system (Veridex) which has FDA approval
for use in metastatic breast, colorectal and prostate cancer.
Enrichment of samples depends upon positive selection of
CTCs that express EpCAM, which means that detection of
malignant cells is limited to those of epithelial origin that
express EpCAM. There is considerable heterogeneity in
EpCAM expression in established epithelial cancer cell
lines.36 Epithelial tumour cells that undergo epithelial mesen-
chymal transition (EMT) lose EpCAM expression and
EpCAM expression changes during the cell cycle.37
A single study has attempted comparison of the Image-
StreamX and CellSearch38 by analysis of PANC-1 pancreatic
cancer cells and reported that the accuracy of enumeration
was lower with the ImageStreamX. The authors enriched the
PANC-1 cells with different methods prior to analysis with
the two platforms which, because the method of enrichment
affects recovery rates, means that the two detection rates are
difficult to evaluate.
There are few reports in the literature about the analysis
of CTCs in oesophageal adenocarcinoma. Survivin mRNA
was detected by RT-PCR in peripheral blood of patients with
a variety of gastrointestinal tumours including oesophageal
adenocarcinoma.39 A recent study using the CellSearch plat-
form assessed CTC numbers in patients with advanced oeso-
phagogastric adenocarcinoma undergoing palliative
chemotherapy.40 The study was ended prematurely due to
the loss of commercial funding. In 11 patients with advanced
oesophageal or oesophagogastric junctional tumours, four
were found to have CTCs. In thyroid cancer, there is again a
lack of evidence for the value of CTC detection. A single
study evaluated the detection carcinoma embryonic antigen
(CEA) mRNA by RT-PCR in 121 patients undergoing surgery
for thyroid cancer41 and detected CTCs in 5% of patients.
EpCAM-positive CTCs were detected with the CellSearch
system in 18 of 59 patients with hepatocellular carcinoma42
and an association between presence of CTCs and overall
survival reported. In another study, CTCs were found in 28%
of HCC patient samples analysed with the CellSearch system
but in 100% of samples analysed with an EpCAM-independ-
ent filtration method.43 In a third study, multi-
immunofluorescence identified considerable heterogeneity
within CTC populations in HCC patients44 and changes in
the ratio of epithelial to mesenchymal cells were associated
with a longer time to disease progression.
There is more extensive literature about the role of CTCs
in ovarian cancer patients. Several studies have isolated a
mononuclear cell fraction by density gradient separation fol-
lowed by positive selection of CTCs based on their expression
of epithelial antigens, usually a single antigen.45,46 In one
study in which cells were enriched sequentially by epithelial
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and leukocyte-specific antigen expression, up to 149 CTCs
were detected per millilitre of blood in 61% of patients under
evaluation for ovarian cancer.47 A wide variation in the
detection rates of CTCs in patients with ovarian cancer of
between 12 and 100% have been reported.5,46,48,49 The high-
est number of CTCs reported is 3,118/ml of blood.45
A large number of methods with different strengths are
described for the enumeration and characterisation of CTCs.
It is unlikely that a single technique will be suitable for all
research and clinical applications. The principle strengths of
the method we describe are the quality of the images pro-
duced, the lack of positive selection of CTCs, its applicability
to all tumour types, and the ability to characterise the biology
of the cancer cells.
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